论文部分内容阅读
抗癌药物不是对任何类型癌都有效,一种特定类型癌的药物敏感性可因人而异,在甚至组织病理学相似的肿瘤之间药物敏感性均有差异。本研究用无菌肿瘤标本和继发肿瘤的腹水在 M119培养基中行组织培养及临床病理学研究。通过记录恶性细胞存活程度评价体外药物效果,对临床药物反应评价:(1)完全缓解(疾病完全消失);(2)部分缓解(疾病减少50%以上);(3)静止状态(可触到肿块减少小于50%或病程未发展);(4)无反应(虽用药物病程继续发展)。结果可见培养成功率在卵巢组织为90%;恶性肿瘤腹水为100%,成功率亦随卵巢恶性肿瘤的类型而异。卵巢肿瘤的培养物对药物反应不同,单用MTX 对培养物几无作用,与其它药物联合应用即有疗效。11例用体外试验最有效或次于最有效药物进行治疗,4例完全缓解,5例部分缓解。2例病情无改变。根据不同敏感试验给药时,总临床有效
Anti-cancer drugs are not effective for any type of cancer. The drug sensitivity of a particular type of cancer can vary from person to person, with differences in drug sensitivity even among tumors of similar histopathology. In this study, aseptic tumor specimens and secondary tumor ascites in M119 medium for tissue culture and clinicopathological studies. The clinical drug response was assessed by recording the extent of malignancy survival in vitro and evaluating clinical drug response: (1) complete remission (complete absence of disease); (2) partial remission (50% reduction of disease); (3) Lumps less than 50% or no course of progression); (4) no response (although the drug course continues to develop). The results showed that the success rate of culture in ovarian tissue was 90%; malignant ascites was 100%, the success rate also varies with the type of ovarian cancer. Cultures of ovarian tumors respond differently to the drug, and MTX alone has few effects on the culture, which is effective in combination with other drugs. Eleven patients were treated with the most effective or second most effective drug in vitro, with complete remission in 4 and partial remission in 5. 2 cases no change in condition. According to different sensitive test when administered, the total clinical effective